Ken Getz, MBA

Adaptive trial designs have the potential to transform success rates, but require new operating strategies and practices.

Public's view of clinical research has improved during the past five years, CISCRP survey reveals.

Active evaluation of non-core procedures is an unusual winwin opportunity for sponsors and CROs.

As integrated alliances assume more risk, novel strategies and practice must follow.

Study coordinators see responsibilities increase dramatically while salary levels remain flat.

From tactical to strategic: tracking the evolution of global clinical supply chain management.

Despite their growing role, little benchmark management data, until now, existed on global study monitors.

Continual change is coming as sponsors' sourcing requirements diverge from the major CROs.

Better selection and tougher site management is not enough to improve enrollment success.

Continual change is coming as sponsors' sourcing requirements diverge from the major CROs.

Compliance with reporting clinical trial results is low, and an even larger opportunity is being missed.

Research shows four factors best predict successful patient enrollment in clinical trials.

Collaborative communities may hold the key to transforming a half-century's old R&D paradigm.

Direction from regulatory agencies would help eradicate wasteful 100 percent source data verification.

Doing more harm than good will ultimately force human subject protection system reform.

Why investigative sites are at financial risk and how it may effect sponsors and CROs.

A recent survey indicates pharmacists should provide more clinical trial information to patients.

New survey from Tufts CSDD and Applied Clinical Trials provides an inside look at global sites.

Reductions in unused data will improve study performance, lower costs, and address ethical concerns.

Mergers and acquisitions volume is way up, but have they fulfilled their intended purpose?

New survey captures sponsors changing global usage of, and relationships with, CRO partners.

Out of necessity, providers may finally become valued strategic partners.

Global clinical trial landscape changes pose new challenges for all sites-even AMCs.

A look at the vague but time consuming requirements imposed on sites and efforts to ease the burden.

Pilot test to rebrand clinical research shows promise as a way to build public trust and promote interest.

Individual countries hold the key to finding hot spots in growth regions like Central and Eastern Europe.

Lack of adequate and attentive support is preventing some sites from fully taking advantage of EDC and ePRO technologies.

A growing trend in the industry has many pharmaceutical companies looking to manage the changing mix of global clinical trial locations.

The FDA's Critical Path Initiative acknowledges long-standing and widely accepted challenges facing the clinical research enterprise and identifies several opportunity areas that may help to address these challenges.

Following more than two decades of growing involvement in nearly all aspects of drug development, full-service and niche-services contract research organizations (CROs) have become a common and integral part of most sponsor companies' clinical research teams.